Clinical Trials Logo

Ovarian Cancer clinical trials

View clinical trials related to Ovarian Cancer.

Filter by:

NCT ID: NCT00179712 Completed - Ovarian Cancer Clinical Trials

Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma

Start date: April 2005
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I will determine the MTD and evaluated the safety profile of oral lenalidomide on days 1-14 when given with topotecan on days 1-5 of every 21 day cycle Phase II will commence once the MTD is established, additional subjects will be enrolled and receive oral lenalidomide on days 1-14 with topotecan on days 1-5 in 21 day cycles until disease progression is documented.

NCT ID: NCT00170690 Completed - Ovarian Cancer Clinical Trials

Preference Study With Elderly Patients Recurrent Ovarian Cancer

Start date: August 2004
Phase: Phase 3
Study type: Interventional

Comparison of the patient compliance treosulfan oral vs. intravenous (defined as end of therapy for the patient)

NCT ID: NCT00170677 Completed - Ovarian Cancer Clinical Trials

Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer

Start date: September 2005
Phase: Phase 2
Study type: Interventional

Comparison of topotecan weekly vs. topotecan day 1-5. The compatibility and activity are to be examined.

NCT ID: NCT00170664 Completed - Ovarian Cancer Clinical Trials

Taxol/ Carboplatin as First Line Therapy in Patients With Epithelial Ovarian Cancer

Start date: January 1999
Phase: Phase 2
Study type: Interventional

The combination of paclitaxel and carboplatin in a three weeks schedule has emerged as the current standard approach for the adjuvant treatment of ovarian cancer. Based on a phase I study now a multi-center phase II-trial was conducted.

NCT ID: NCT00170625 Completed - Ovarian Cancer Clinical Trials

Therapy With Topotecan and Carboplatin by Patients With Relapsed Ovarian Cancer

Start date: June 2004
Phase: Phase 1/Phase 2
Study type: Interventional

Compatibility of the topotecan therapy in combination with carboplatin.

NCT ID: NCT00170573 Completed - Ovarian Cancer Clinical Trials

Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer

Start date: October 2001
Phase: Phase 2
Study type: Interventional

Pegylated liposomal doxorubicin (PLD) formulation has been approved for the treatment of recurrent ovarian cancer (ROC). Toxic skin reactions were reported as being the dose-limiting toxicity and have an impact on patients' quality of life (QoL). The primary aim of this study was to optimise the toxicity profile by choosing a biweekly schedule of PLD Furthermore, QoL was investigated. Secondary objective of this study was to evaluate the response rates of this new regimen.

NCT ID: NCT00165152 Completed - Breast Cancer Clinical Trials

Counseling Interventions for BRCA 1/2 Cancer Susceptibility Testing

Start date: July 1998
Phase: N/A
Study type: Interventional

To evaluate two different ways of providing information about genetic testing for BRCA1 and BRCA2 alterations. The two forms of counseling are genetic counseling and enhanced informed consent which cover similar material but are organized differently.

NCT ID: NCT00164658 Completed - Breast Cancer Clinical Trials

Evaluating Tools for Health Promotion and Disease Prevention

Start date: September 2005
Phase: Phase 1
Study type: Interventional

The study will evaluate the effect of familial risk assessment and prevention prompts tailored to familial risk on health behaviors and use of preventive services among adults who are members of primary care practices in the U.S.

NCT ID: NCT00158379 Completed - Ovarian Cancer Clinical Trials

Taxol Carboplatin and Erythropoetin

Start date: July 2003
Phase: Phase 2
Study type: Interventional

Time to progression (physical examination and radiologic imaging

NCT ID: NCT00157573 Completed - Ovarian Cancer Clinical Trials

GM-CSF in Women With Recurrent Ovary Cancer

Start date: December 2004
Phase: Phase 2
Study type: Interventional

GM-CSF is an immunostimulant and preliminary data suggests it may change the natural history of prostate cancer and melanoma. This study looks at ability of GM-CSF to alter disease progression in women who have recurrent but asymptomatic recurrence of their ovarian cancer.